

## 1. Company details

Name of entity:	Prescient Therapeutics Limited
ABN:	56 006 569 106
Reporting period:	For the half-year ended 31 December 2022
Previous period:	For the half-year ended 31 December 2021

## 2. Results for announcement to the market

			\$
Revenues from ordinary activities	up	868.5% to	137,228
Loss from ordinary activities after tax attributable to the owners of Prescient Therapeutics Limited	up	10.1% to	(2,879,698)
Loss for the half-year attributable to the owners of Prescient Therapeutics Limited	up	10.1% to	(2,879,698)

### Dividends

There were no dividends paid, recommended or declared during the current financial period.

### Comments

The loss for the consolidated entity after providing for income tax amounted to \$2,879,698 (31 December 2021: \$2,615,863).

### Financial performance

The consolidated entity has accounted for an estimated research and development incentive rebate for the half year amounting to \$1,204,589 (31 December 2021: \$812,480) for R&D expenses amounting to \$2,453,280 (2021: \$1,613,699) incurred during the half-year, which has been recognised in the statement of profit or loss for the half year.

Overall operating expenses increased to \$4,271,515 (31 December 2021: \$3,472,512), due to increase in R&D activities and experts appointed compared to the prior period.

### Financial position

Net assets have increased to \$24,802,617 (30 June 2022: \$16,762,412), mainly attributable to completion of share purchase plan and top up placement during the half year raised approximately \$11,280,442 before costs. The business is in a strong financial position following the success of the current period capital raise through Share Purchase Plan of \$8,779,694 and Top-Up Placement of \$2,500,748 before capital raising cost.

Other key movements include decrease in the R&D tax incentive receivable from \$1,640,505 to \$1,204,589, as the current period balance only relates to the estimation for the half year ended 31 December 2021, compared to the prior period balance which relates to the entire financial year.

## 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>2.97</u>	<u>2.05</u>

## 4. Control gained over entities

Not applicable.

## 5. Loss of control over entities

Not applicable.

---

## 6. Dividends

### *Current period*

There were no dividends paid, recommended or declared during the current financial period.

### *Previous period*

There were no dividends paid, recommended or declared during the previous financial period.

---

## 7. Dividend reinvestment plans

Not applicable.

---

## 8. Details of associates and joint venture entities

Not applicable.

---

## 9. Foreign entities

### *Details of origin of accounting standards used in compiling the report:*

Not applicable.

---

## 10. Audit qualification or review

### *Details of audit/review dispute or qualification (if any):*

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

---

## 11. Attachments

### *Details of attachments (if any):*

The Interim Report of Prescient Therapeutics Limited for the half-year ended 31 December 2022 is attached.

---

## 12. Signed

Signed Stan Engle

Date: 24 February 2023

Mr Steven Engle  
Non-Executive Chairman

# **Prescient Therapeutics Limited**

**ABN 56 006 569 106**

**Interim Report - 31 December 2022**

For personal use only

**Prescient Therapeutics Limited**  
**Contents**  
**31 December 2022**



Corporate directory	2
Directors' report	3
Auditor's independence declaration	7
Statement of profit or loss and other comprehensive income	8
Statement of financial position	9
Statement of changes in equity	10
Statement of cash flows	11
Notes to the financial statements	12
Directors' declaration	17
Independent auditor's review report to the members of Prescient Therapeutics Limited	18

For personal use only

Directors	Mr Steven Engle (Non-Executive Chairman) Mr Steven Yatomi-Clarke (Managing Director and CEO) Dr James Campbell (Non-Executive Director) Dr Allen Ebens (Non-Executive Director)
Company secretary	Ms Melanie Leydin
Registered office	Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Phone: 03 9692 7222
Principal place of business	Level 4, 96-100 Albert Road South Melbourne VIC 3205
Share register	Automic Registry Services Level 5 126 Phillip Street Sydney NSW 2000 Phone: 02 9698 5414
Auditor	William Buck Level 20, 181 William Street Melbourne VIC 3000
Stock exchange listing	Prescient Therapeutics Limited securities are listed on the Australian Securities Exchange (ASX code: PTX and PTXOC)
Website	<a href="https://ptxtherapeutics.com">https://ptxtherapeutics.com</a>

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Prescient Therapeutics Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2022.

### **Directors**

The following persons were Directors of Prescient Therapeutics Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

- Mr Steven Engle (Non-Executive Chairman)
- Mr Steven Yatomi-Clarke (Managing Director and CEO)
- Dr James Campbell (Non-Executive Director)
- Dr Allen Ebens (Non-Executive Director)

### **Principal activities**

During the financial half-year, the principal continuing activities of the consolidated entity consisted of:

- the preparation for and conduct of research and development of the Company's proprietary technologies and products; and
- business development associated with the developing collaborative, partnership relationships, corporate transactions and promotion of Prescient's proprietary technologies and products.

### **Review of operations**

The loss for the consolidated entity after providing for income tax amounted to \$2,879,698 (31 December 2021: \$2,615,863).

Prescient continued to meet its clinical and development milestones. The business is in a sound financial position and its cancer therapy programs continue to attract clinical, institutional and commercial interest.

### **Targeted Therapies**

#### **PTX-100**

PTX-100 continues to show an encouraging efficacy and safety profile in patients with relapsed and refractory T cell lymphomas (TCL), including peripheral and cutaneous TCL. Following in the efficacy signal in the dose escalation stage of a Phase 1b basket study, the trial progressed to an expansion cohort of 12 patients with relapsed and refractory TCL under the leadership of globally-renowned lymphoma expert, Professor H. Miles Prince, AM.

During the period, the US Food and Drug Administration (FDA) granted Orphan Drug Designation to PTX-100 as a treatment for PTCL.

The designation gives special status to drugs intended for the treatment of rare diseases that affect fewer than 200,000 people in the US. The benefits include a guaranteed market for seven years after regulatory approval and a waiver of Prescription Drug User Fee Act (PDUFA) fees once the drug is on the market.

#### **PTX-200**

During the period Prescient's other targeted therapy, the novel PH domain inhibitor PTX 200, endured disruptions for recruitment during its phase 1B trial for relapse and refractory acute leukaemia, due to staffing shortages at an institutional level at the Moffitt Cancer Centre where the trial is being conducted. Pleasingly, these staffing issues have been resolved and the trial is back on track. So far on this study there have been four patients that have experienced complete responses and another patient with a partial response. Following completion of the current cohort at 45mg/m<sup>2</sup> PTX-200 in combination with cytarabine, Prescient will work with the investigators to determine the optimum path forward for this drug having consideration to the clinical performance of the drug combination, the evolving standard of care in this disease, the competitive landscape and also the limitations over the patents.

## **Cell Therapies**

### **OmniCAR**

During the period, Prescient announced a strategic collaboration with the largest cancer centre in the US, The University Texas MD Anderson Cancer Centre (MD Anderson) to deliver best-in-class, adaptable CAR-T cell therapies to treat hematological malignancies. This collaboration with MD Anderson continues Prescient's track record of partnering with world-leading cancer research organisations. The collaboration will seek to combine Prescient's OmniCAR modular 'plug and play' CAR platform with an undisclosed, proprietary TCR-like binder discovered by MD Anderson's Evolution of Leukemia and Immunity Post Stem cell transplant platform, also known as ECLIPSE.

Prescient also entered a manufacturing services agreement with specialist cell therapy manufacturer, Q-Gen Cell Therapeutics (Q-Gen), to produce its OmniCAR cell lines for forthcoming clinical trials. Manufacturing will take place at Q-Gen's dedicated Brisbane facility, which produces autologous and allogeneic cell therapies for local and international pharmaceutical companies and academic research groups. Q-Gen is the cell therapy manufacturing arm of the QIMR Berghofer Medical Research Institute and is one of Australia's leading producers of cell-based medicines. Prescient has commenced the technology transfer process for OmniCAR-T cell manufacturing.

Q-Gen will also incorporate Prescient's cell manufacturing enhancement, CellPryme-M into the manufacturing process of OmniCAR T cells, to produce a more effective and longer lasting T cell phenotype.

During the period, Prescient announced a material transfer agreement with a large international company to evaluate the potential of utilizing an automated, closed process for manufacturing OmniCAR T cells using non-viral methods.

A key objective for Prescient is to manufacture OmniCAR with greater efficiency, higher reproducibility and lower costs that are suitable for technology transfer to third party manufacturers. This aligns with Prescient's vision of decentralized manufacturing which is ideally suited for multi-centre studies and eventually for commercial roll-out.

A key patent in the OmniCAR portfolio was granted in the US during the period. The granting of US Patent No 11,377,481 entitled "*SpyCatcher and SpyTag: Universal Immune Receptor For T Cells*" provides protection for the Company's valuable intellectual property in the world's largest healthcare market until 2039.

### **CellPryme**

Prescient's new cell therapy enhancement platform, CellPryme-A, emerged from stealth mode during the period, at the annual CAR-TCR Summit in Boston. CellPryme-A is an adjuvant therapy administered to cancer patients in combination with cellular immunotherapy and address the hostile tumour microenvironment that reduce the effectiveness of cellular immunotherapies.

CellPryme-A boosts the tumour killing capabilities of CAR-T therapies and improves host survival in highly resistant, syngeneic animal models. It does this by reducing the number of suppressive regulatory T cells surrounding solid tumours that counteract the effectiveness of CAR-T and other cancer therapies; dramatically enhancing CAR-T expansion *in vivo*, and increasing CAR-T cell penetration into tumours. The beneficial effects were even greater when CellPryme-A was used in combination with CAR-T cells that incorporated CellPryme-M into their manufacturing process.

Although only recently disclosed, both CellPryme technologies have started to generate strong interest among the international clinical community and doctors working to overcome the limitations of current CAR-T therapies. Both CellPryme technologies are ready for clinical trials, with suitable material readily available.

### **Funding**

Prescient topped up its cash reserves during the period with a Share Purchase Plan (SPP) to existing shareholders that raised gross proceeds of \$8.8 million, followed by a top-up placement that raised an additional \$2.5 million. Together, \$11.3 million was raised, providing ongoing financial security amidst macroeconomic uncertainty as the business seeks to continue to deliver on important milestones. The Company is very appreciative of the support and confidence from its shareholders who participated in the capital raising.

An Australian Government Research and Development tax refund of \$1.6 million was also received in November 2022.

### **Outlook**

The reporting period was significant in the growth of the Company to date and the business seeks to maintain the positive momentum and build on the successes achieved to date.

### **Key risks and uncertainties**

The Company is subject to both specific to the Company and the Company's business activities, as well as general risks.

#### *Technical risks*

The inherent nature of research and development is uncertain. There are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. This would have a material impact on the Company.

The Company is mitigating this risk where reasonably possible through diversification of its product pipeline, undertaking rigorous scientific review during the development process, and working with reputable and capable partners and service providers.

#### *Future funding risks*

Whilst the Company has a cash and cash equivalents of \$20,951,585 and net assets of \$24,802,617 and is able to continue on a going concern basis. However, there is risk that the Company may require substantial additional financing in the future to sufficiently fund its operations, research and development.

In addition, in many territories, products such as those being developed by the Company, must follow a formal reimbursement process in order to be commercially successful. The availability and timing of reimbursement may have an impact upon the uptake and profitability of products in some jurisdictions.

The Directors regularly review the spending pattern and ability to raise additional fund to ensure the Company's ability to generate sufficient cash inflows to settle its creditors and other liabilities. In addition, the Company is eligible for certain government grants and R&D tax incentive.

#### *Regulatory and licensing risks*

if the Company does not obtain the necessary regulatory approvals it may be unable to commercialise its pharmaceutical products. Even if it receives regulatory approval for any product candidates, profitability will depend on its ability to generate revenues from the sale of its products or the licensing of its technology.

The Company monitors legislative and regulatory developments and engages proactively with key stakeholders to manage this risk.

#### *Dependence on commercial partners and future licence arrangements*

There is no guarantee that the Company will be able to find suitable industry partners that it can negotiate attractive commercial terms for future licence agreements for new or its existing products. The success of the Company's partnering arrangements may depend on resources devoted to them by itself or its industry partners. Collaborative agreements may be terminable by the Company's partners. Non-performance, suspension or termination of relevant agreements is likely to have a material and adverse impact on the Company's business, financial condition and results of operations.

The Company monitors commercial developments and engages proactively with key stakeholders to manage this risk.

#### *Reliance on key personnel*

The Company's success depends to a significant extent upon its key management personnel, as well as other management and technical personnel including those employed on a contractual basis. The loss of the services of such personnel or the reduced ability to recruit additional personnel could have an adverse effect on the performance of the Company.

The Company maintains a mixture of in-house personnel and external consultants to allow the access of multiple sources of resources, and through the Remuneration and nomination committee reviews remunerations to human resources regularly.

#### *Inability to protect intellectual property*

The Company's ability to leverage its innovation and expertise is dependent on its ability to protect its intellectual property and any improvements to it. A failure or inability to protect the Company's intellectual property rights could have an adverse impact on operating and financial performance.

The Company proactively monitors applications and renewals of patents and licences; and requires relevant stakeholders to comply with the requirements set out in the confidentiality policy.

#### *IT system failure and cyber security risks*

Any information technology system is potentially vulnerable to interruption and/or damage from a number of sources, including but not limited to computer viruses, cyber security attacks and other security breaches, power, systems, internet



and data network failures, and natural disasters.

The Company is committed to preventing and reducing cyber security risks through outsourced the IT management to a reputable services provider. In addition, the Company has an insurance policy covering IT and cyber security matters.

**Significant changes in the state of affairs**

In October 2022, the Company issued 64,459,666 shares at \$0.175 each and raised \$11,280,442 before transaction costs from a share purchase plan and top-up placement.

During the half year ended 31 December 2022, the Company issued 1,273,765 shares at \$0.0625 each and raised \$79,610 from exercise of listed options.

**Matters subsequent to the end of the financial half-year**

Subsequent to 31 December 2022, the Company has issued 5,074,460 shares at \$0.0625 per share (6.25 cents) from the exercise of listed options raising \$317,154.


No other matter or circumstance has arisen since 31 December 2022 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

**Auditor's independence declaration**

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report.

This report is made in accordance with a resolution of Directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the Directors



Mr Steven Engle  
Non-Executive Chairman

24 February 2023

## AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001 TO THE DIRECTORS OF PRESCIENT THERAPEUTICS LIMITED

I declare that, to the best of my knowledge and belief, during the half-year ended 31 December 2022 there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- no contraventions of any applicable code of professional conduct in relation to the review.

William Buck

**William Buck Audit (Vic) Pty Ltd**

ABN 59 116 151 136



**N. S. Benbow**

Director

Melbourne, 24 February 2023

**Prescient Therapeutics Limited**  
**Statement of profit or loss and other comprehensive income**  
**For the half-year ended 31 December 2022**



	Note	Consolidated 2022 \$	2021 \$
<b>Interest revenue</b>		137,228	14,169
Other income	4	1,254,589	842,480
<b>Expenses</b>			
Research and development costs		(2,453,280)	(1,613,699)
Employment expenses		(848,355)	(815,412)
Corporate and administrative expenses		(714,394)	(549,992)
Share based payments		(257,669)	(512,493)
Interest expenses		-	(6,534)
Foreign exchange movements		2,183	25,618
<b>Loss before income tax expense</b>		(2,879,698)	(2,615,863)
Income tax expense		-	-
<b>Loss after income tax expense for the half-year attributable to the owners of Prescient Therapeutics Limited</b>		(2,879,698)	(2,615,863)
Other comprehensive income for the half-year, net of tax		-	-
<b>Total comprehensive income for the half-year attributable to the owners of Prescient Therapeutics Limited</b>		<u>(2,879,698)</u>	<u>(2,615,863)</u>
		<b>Cents</b>	<b>Cents</b>
Basic loss per share	12	(0.42)	(0.41)
Diluted loss per share	12	(0.42)	(0.41)

*The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

**Prescient Therapeutics Limited**  
**Statement of financial position**  
**As at 31 December 2022**



		<b>Consolidated</b>	
	<b>Note</b>	<b>31 December</b>	<b>30 June 2022</b>
		<b>2022</b>	<b>2022</b>
		<b>\$</b>	<b>\$</b>
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	5	20,951,585	12,263,839
Trade and other receivables		203,224	77,726
Term deposits		20,000	20,000
Prepayments		134,485	244,557
Research and Development Claims Receivable		1,204,589	1,640,505
<b>Total current assets</b>		<u>22,513,883</u>	<u>14,246,627</u>
<b>Non-current assets</b>			
Property, plant and equipment		3,848	4,904
Intangibles		3,366,894	3,366,894
<b>Total non-current assets</b>		<u>3,370,742</u>	<u>3,371,798</u>
<b>Total assets</b>		<u>25,884,625</u>	<u>17,618,425</u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables		855,766	663,412
Employee benefits		118,226	120,101
Fund received in advance for exercise of share options		56,793	25,563
<b>Total current liabilities</b>		<u>1,030,785</u>	<u>809,076</u>
<b>Non-current liabilities</b>			
Employee benefits		51,223	46,937
<b>Total non-current liabilities</b>		<u>51,223</u>	<u>46,937</u>
<b>Total liabilities</b>		<u>1,082,008</u>	<u>856,013</u>
<b>Net assets</b>		<u>24,802,617</u>	<u>16,762,412</u>
<b>Equity</b>			
Issued capital	6	87,951,653	77,264,264
Reserves		2,129,501	1,950,233
Accumulated losses		(65,278,537)	(62,452,085)
<b>Total equity</b>		<u>24,802,617</u>	<u>16,762,412</u>

*The above statement of financial position should be read in conjunction with the accompanying notes*

**Prescient Therapeutics Limited**  
**Statement of changes in equity**  
**For the half-year ended 31 December 2022**



<b>Consolidated</b>	<b>Issued capital</b> \$	<b>Share Based Payments Reserve</b> \$	<b>Share Loan Plan Reserve</b> \$	<b>Accumulated losses</b> \$	<b>Total equity</b> \$
Balance at 1 July 2021	76,671,176	898,437	365,276	(57,507,622)	20,427,267
Loss after income tax expense for the half-year	-	-	-	(2,615,863)	(2,615,863)
Other comprehensive income for the half-year, net of tax	-	-	-	-	-
Total comprehensive income for the half-year	-	-	-	(2,615,863)	(2,615,863)
<i>Transactions with owners in their capacity as owners:</i>					
Contributions of equity, net of transaction costs	326,222	(24,529)	-	-	301,693
Vesting of Share-based payments	-	479,145	33,348	-	512,493
Lapsed/expired options	-	(4,093)	-	4,093	-
Balance at 31 December 2021	<u>76,997,398</u>	<u>1,348,960</u>	<u>398,624</u>	<u>(60,119,392)</u>	<u>18,625,590</u>

<b>Consolidated</b>	<b>Issued capital</b> \$	<b>Share Based Payments Reserve</b> \$	<b>Share Loan Plan Reserve</b> \$	<b>Accumulated losses</b> \$	<b>Total equity</b> \$
Balance at 1 July 2022	77,264,264	1,625,609	324,624	(62,452,085)	16,762,412
Loss after income tax expense for the half-year	-	-	-	(2,879,698)	(2,879,698)
Other comprehensive income for the half-year, net of tax	-	-	-	-	-
Total comprehensive income for the half-year	-	-	-	(2,879,698)	(2,879,698)
<i>Transactions with owners in their capacity as owners:</i>					
Exercise of listed share options (note 6)	79,610	-	-	-	79,610
Exercise of unlisted share options (note 6)	25,155	(25,155)	-	-	-
Vesting of Share-based payments	-	257,669	-	-	257,669
Shares issued from share purchase plan and top up placement	11,280,442	-	-	-	11,280,442
Transaction costs	(697,818)	-	-	-	(697,818)
Lapse or expiry of unlisted share options	-	(53,246)	-	53,246	-
Balance at 31 December 2022	<u>87,951,653</u>	<u>1,804,877</u>	<u>324,624</u>	<u>(65,278,537)</u>	<u>24,802,617</u>

The above statement of changes in equity should be read in conjunction with the accompanying notes

**Prescient Therapeutics Limited**  
**Statement of cash flows**  
**For the half-year ended 31 December 2022**



	<b>Consolidated</b>	
	<b>2022</b>	<b>2021</b>
	<b>\$</b>	<b>\$</b>
<b>Cash flows from operating activities</b>		
Payments to suppliers and employees (inclusive of GST)	(3,775,885)	(2,829,776)
Interest received	77,480	10,301
R&D tax incentive received	1,640,506	1,295,997
Other grants received	50,000	30,000
	<hr/>	<hr/>
Net cash used in operating activities	(2,007,899)	(1,493,478)
	<hr/>	<hr/>
Net cash from investing activities	-	-
	<hr/>	<hr/>
<b>Cash flows from financing activities</b>		
Proceeds from issue of shares	11,280,442	-
Proceeds from the exercise of listed share options for shares	110,840	304,193
Capital raising costs	(697,818)	(2,500)
Repayment of funding for insurance premium	-	(165,829)
	<hr/>	<hr/>
Net cash from financing activities	10,693,464	135,864
	<hr/>	<hr/>
Net increase/(decrease) in cash and cash equivalents	8,685,565	(1,357,614)
Cash and cash equivalents at the beginning of the financial half-year	12,263,839	16,097,508
Effects of exchange rate changes on cash and cash equivalents	2,181	25,618
	<hr/>	<hr/>
Cash and cash equivalents at the end of the financial half-year	<u>20,951,585</u>	<u>14,765,512</u>

*The above statement of cash flows should be read in conjunction with the accompanying notes*

## **Note 1. General information**

The financial statements cover Prescient Therapeutics Limited as a consolidated entity consisting of Prescient Therapeutics Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Prescient Therapeutics Limited's functional and presentation currency.

Prescient Therapeutics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Level 4, 100 Albert Road  
South Melbourne, VIC, 3205

A description of the nature of the consolidated entity's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of Directors, on 24 February 2023.

## **Note 2. Significant accounting policies**

These general purpose financial statements for the interim half-year reporting period ended 31 December 2022 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2022 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with the most recent Annual Report for the year ended 30 June 2022.

### **New or amended Accounting Standards and Interpretations adopted**

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

## **Note 3. Operating segments**

### *Identification of reportable operating segments*

The Company operated predominately in the clinical stage oncology industry within Australia. AASB 8 requires operating segments to be identified on the basis of internal reports about the components of the Group that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance. The board reviews the Company as a whole in the business segment of clinical stage oncology within Australia.

#### Note 4. Other income

	Consolidated	
	2022	2021
	\$	\$
Government grants	50,000	30,000
R&D tax incentive	1,204,589	812,480
Other income	<u>1,254,589</u>	<u>842,480</u>

The Research and Development Tax Incentive programme provides tax offsets for expenditure on eligible R&D activities. Under the programme, Prescient, having expected aggregated annual turnover of under \$20 million, is entitled to a refundable R&D credit of 43.5% on the eligible R&D expenditure incurred on eligible R&D activities. One of the conditions the company must meet is ensuring more than 50% of total R&D activity costs will be incurred in Australia.

During the period, the consolidated entity recognised R&D tax incentive revenue of \$ 1,204,589 (31 December 2021: \$812,480).

#### Note 5. Cash and cash equivalents

	Consolidated	
	31 December 2022	30 June 2022
	\$	\$
<i>Current assets</i>		
Cash at bank	6,951,585	4,263,839
Cash on deposit	14,000,000	8,000,000
	<u>20,951,585</u>	<u>12,263,839</u>

#### Note 6. Issued capital

	Consolidated			
	31 December 2022	30 June 2022	31 December 2022	30 June 2022
	Shares	Shares	\$	\$
Ordinary shares - fully paid	<u>720,698,195</u>	<u>654,323,053</u>	<u>87,951,653</u>	<u>77,264,264</u>

#### Movements in ordinary share capital

Details	Date	Shares	\$	
Balance	1 July 2022	654,323,053		77,264,264
Exercise of listed share options	22 July 2022	409,000	\$0.063	25,563
Exercise of listed share options	1 September 2022	44,000	\$0.063	2,750
Exercise of listed share options	9 September 2022	12,906	\$0.063	807
Share purchase plan	11 October 2022	50,169,674	\$0.175	8,779,694
Exercise of listed share options	13 October 2022	342,921	\$0.063	21,433
Top-up placement	17 October 2022	14,289,992	\$0.175	2,500,748
Exercise of listed share options	15 November 2022	218,000	\$0.063	13,623
Exercise of listed share options	8 December 2022	246,938	\$0.063	15,434
Exercise of unlisted share options	14 December 2022	641,711	\$0.039	25,155
Transaction costs		-	\$0.000	(697,818)
Balance	31 December 2022	<u>720,698,195</u>		<u>87,951,653</u>



#### Note 6. Issued capital (continued)

\* Transaction costs of \$697,818 were directly attributed to the capital raise from Share Purchase Plan and Top-Up Placement and deducted from equity as a result.

#### Note 7. Dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

#### Note 8. Contingent Liabilities and commercial agreements that may impact future operations

There has been no change to the agreements since 30 June 2022. The consolidated entity has entered into several agreements whereby it is obliged to make royalty payments on future sales and make future cash milestone payments if certain events occur. These agreements include the following:

##### *Yale University*

The agreement includes:

- Milestone payments based on dosing of patients in trials
- Milestone payments based on First New Drug Application (NDA) for a licensed product, and the associated FDA approval of the NDA
- Milestone payments based on market entry of licensed products in certain countries
- Royalty payments based on worldwide annual net sales

##### *Cahaba Pharmaceuticals LLC*

The agreement includes:

- Payments derived from achievement of clinical success-based milestones
- Milestone payments based on FDA acceptance of trials conducted
- Milestone payments based on dosing of patients in trials
- Milestone payments based on First New Drug Application (NDA) for a licensed product, and the associated FDA approval of the NDA
- Royalty payments based on net sales and sublicensing revenue

##### *University of Pennsylvania*

The agreement includes:

- Development milestone payments based on first dosing of a subject in phases of clinical trials
- Milestone payments based on reaching certain levels of product net sales
- Royalties paid on levels of annual product net sales

##### *Oxford University*

The agreement includes:

- Royalties paid on net sales of a licensed product
- Milestone payments based on commencement of phases and first regulatory approval of products

## Note 9. Commitments

There has been no change to the agreements since 30 June 2022. The consolidated entity has entered into a number of licence agreements as outlined below:

### *Yale University License agreement - PTX 100*

An agreement was entered into to license certain intellectual property and technology from Yale University. As part of the agreement the consolidated entity is required to pay annual license maintenance fees.

### *Cahaba Pharmaceuticals LLC - PTX 200*

An agreement was entered into to license certain intellectual property and technology from Cahaba Pharmaceuticals LLC. As part of the agreement the consolidated entity is required to pay annual license maintenance fees.

### *University of Pennsylvania License agreement - OmniCAR*

An agreement was entered into to license certain intellectual property and technology from University of Pennsylvania. As part of the agreement the consolidated entity is required to pay annual license maintenance fees.

### *Oxford University License agreement - OmniCAR*

An agreement was entered into to license certain intellectual property and technology from Oxford University. As part of the agreement the consolidated entity is required to pay annual license maintenance fees.

## Note 10. Related party transactions

### *Key management personnel*

The Employee Loan Funded Share ("LFS") arrangement with Mr Steven Yatomi-Clark is executed between the Company and Arrow Wealth Pty Limited, of which Mr Steven Yatomi-Clark is a Director. As at 31 December 2022, the total fully paid ordinary shares issued and the loan balance under the Plan were 6,000,000 and \$928,000 respectively, with the Company having recourse to the outstanding loan balance limited to the shares issued under the plan to Mr Steven Yatomi-Clarke or his nominee entity, Arrow Wealth Pty Ltd. There has been no change to LFS arrangement since 30 June 2022.

## Note 11. Events after the reporting period

Subsequent to 31 December 2022, the Company has issued 5,074,460 shares at \$0.0625 per share (6.25 cents) from the exercise of listed options raising \$317,154.

No other matter or circumstance has arisen since 31 December 2022 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

## Note 12. Loss per share

	<b>Consolidated</b>	
	<b>2022</b>	<b>2021</b>
	<b>\$</b>	<b>\$</b>
Loss after income tax attributable to the owners of Prescient Therapeutics Limited	<u>(2,879,698)</u>	<u>(2,615,863)</u>
	<b>Number</b>	<b>Number</b>
Weighted average number of ordinary shares used in calculating basic earnings per share	<u>682,922,188</u>	<u>644,585,425</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>682,922,188</u>	<u>644,585,425</u>
	<b>Cents</b>	<b>Cents</b>
Basic loss per share	(0.42)	(0.41)
Diluted loss per share	(0.42)	(0.41)

**Note 12. Loss per share (continued)**

The rights to options held by option holders have not been included in the weighted average number of ordinary shares for the purposes of calculating diluted EPS as they do not meet the requirements for inclusion in AASB 133 'Earnings Per Share'. The rights to options are non-dilutive as the consolidated entity is loss generating.

For personal use only

**Prescient Therapeutics Limited**  
**Directors' declaration**  
**31 December 2022**



In the Directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2022 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of Directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the Directors

A handwritten signature in black ink that reads "Steven Engle".

Mr Steven Engle  
Non-Executive Chairman

24 February 2023

## Prescient Therapeutics Limited Independent auditor's review report

### REPORT ON THE REVIEW OF THE HALF-YEAR FINANCIAL REPORT

#### Conclusion

We have reviewed the accompanying half-year financial report of Prescient Therapeutics Limited (the Company) and the entities it controlled at the half-year's end or from time to time during the half year (the consolidated group), which comprises the consolidated statement of financial position as at 31 December 2022, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Prescient Therapeutics Limited is not in accordance with the *Corporations Act 2001* including:

- a. giving a true and fair view of the consolidated entity's financial position as at 31 December 2022 and of its performance for the half year ended on that date; and
- b. complying with Australian Accounting Standard 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

#### Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

#### Responsibility of Management for the Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

## Auditor's Responsibilities for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Company's financial position as at 31 December 2022 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

William Buck

**William Buck Audit (Vic) Pty Ltd**

ABN 59 116 151 136



**N. S. Benbow**

Director

Melbourne, 24 February 2023

For personal use only